Pioglitazone initiation and subsequent hospitalization for congestive heart failure
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Aims Thiazolidinediones (TZD) have been associated with an expansion in plasma volume and the development of peripheral oedema. A recent study reported an association between the use of TZDs and development of congestive heart failure (CHF). The objective of this study was to determine if short‐term use of pioglitazone, a TZD, is associated with increased risk of admission to hospital because of CHF in a well‐characterized, community‐based cohort of Type 2 diabetic patients without prevalent CHF. Methods A cohort study of all patients in the Kaiser Permanente Medical Care Program with Type 2 diabetes (Kaiser Permanente Northern California Diabetes Registry) who initiated any diabetes pharmacotherapy (n = 23 440) between October 1999 and November 2001. Only patients initiating single new therapies (‘new users’) were included to reduce confounding and create mutually exclusive exposure groups. We constructed Cox proportional hazards models (with sulphonylureas initiators specified as the reference group) to evaluate the impact of initiating new diabetes therapies on time‐to‐incident admission to hospital because of CHF, defined by primary hospital discharge diagnosis. Results Patients initiated pioglitazone (15.2%), sulphonylureas (25.3%), metformin (50.9%), and insulin (8.6%) alone, or as additions to pre‐existing or maintained therapies. Three hundred and twenty admissions for CHF were observed during the follow‐up (mean 10.2 months) after drug initiation. Relative to patients initiating sulphonylureas, there were no significant increases in the incidence of hospitalization for CHF in those initiating pioglitazone [hazard ratio (HR) = 1.28; 95% confidence interval (CI): 0.85–1.92] after adjusting for demographic, behavioural and clinical factors. There was a significantly higher incidence among those initiating insulin (HR = 1.56; 95% CI: 1.00–2.45) and lower incidence among those initiating metformin (HR = 0.70; 95% CI: 0.49–0.99). Conclusions This study of patients with Type 2 diabetes failed to find evidence that short‐term pioglitazone use was associated with an elevated risk of hospitalization for CHF relative to the standard, first‐line diabetes therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The natural history of congestive heart failure: the Framingham study
McKee, P. A., Castelli, W. P., McNamara, P. M., & Kannel, W. B. (1971) · New England Journal of Medicine · doi:10.1056/nejm197112232852601 · Cited by 3,448
A comparison of observational studies and randomized, controlled trials.
Benson, K., & Hartz, A. J. (2000) · New England Journal of Medicine · doi:10.1056/nejm200006223422506 · Cited by 2,347
Evaluating medication effects outside of clinical trials: new-user designs
Ray, W. A. (2003) · American Journal of Epidemiology · doi:10.1093/aje/kwg231 · Cited by 1,646 · cited 7×
“The major strengths of this study is the “new-user” design, and thereby its avoidance of chronology bias introduced when new users of drugs are compared to ongoing users of drugs(10;36).”
BackgroundMethodInfluentialEthnic disparities in diabetic complications in an insured population
Karter, A. J. (2002) · JAMA · doi:10.1001/jama.287.19.2519 · Cited by 840 · cited 1×
“(16-27) Registry sensitivity was estimated to be 99% in 2001 based on the inclusion of patients in the registry who self-report diabetes in a general membership health survey.”
BackgroundSelf-citationThe Incidence of Congestive Heart Failure in Type 2 Diabetes
Nichols, G. A., Gullion, C. M., Koro, C. E., Ephross, S. A., & Brown, J. B. (2004) · Diabetes Care · doi:10.2337/diacare.27.8.1879 · Cited by 812
Miyazaki, Y., Mahankali, A., Matsuda, M., Mahankali, S., Hardies, J., Cusi, K., Mandarino, L. J., & DeFronzo, R. A. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.6.8567 · Cited by 726
Karter, A. J., Ackerson, L. M., Darbinian, J. A., D’Agostino, R. B., Ferrara, A., Liu, J., & Selby, J. V. (2001) · The American Journal of Medicine · doi:10.1016/s0002-9343(01)00742-2 · Cited by 595
Self-citationMasoudi, F. A., Inzucchi, S. E., Wang, Y., Havranek, E. P., Foody, J. M., & Krumholz, H. M. (2005) · Circulation · doi:10.1161/01.cir.0000154542.13412.b1 · Cited by 458
Assessment and Control for Confounding by Indication in Observational Studies
Psaty, B. M., Koepsell, T. D., Lin, D., Weiss, N. S., Siscovick, D. S., Rosendaal, F. R., Pahor, M., & Furberg, C. D. (1999) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1999.tb01603.x · Cited by 363 · cited 1×
“Observational studies are particularly vulnerable to bias because there may be substantial imbalance in risk of events or disease severity between therapy exposure groups (confounding by indication(35)).”
Background
Cited by
Good and poor adherence: optimal cut-point for adherence measures using administrative claims data.
Karve, S., Cleves, M. A., Helm, M., Hudson, T. J., West, D. S., & Martin, B. C. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990903126833 · Cited by 620
Qaseem, A., Humphrey, L. L., Sweet, D. E., Starkey, M., Shekelle, P., & for the Clinical Guidelines Committee of the American College of Physicians* (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-156-3-201202070-00011 · Cited by 400
Erdmann, E., Dormandy, J. A., Charbonnel, B., Massi-Benedetti, M., Moules, I. K., & Skene, A. M. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.12.048 · Cited by 378
Eurich, D. T., McAlister, F. A., Blackburn, D. F., Majumdar, S. R., Tsuyuki, R. T., Varney, J., & Johnson, J. A. (2007) · BMJ · doi:10.1136/bmj.39314.620174.80 · Cited by 362
Thiazolidinediones and Cardiovascular Outcomes in Older Patients With Diabetes
Lipscombe, L. L., Gomes, T., Lévesque, L. E., Hux, J. E., Juurlink, D. N., & Alter, D. A. (2007) · JAMA · doi:10.1001/jama.298.22.2634 · Cited by 345
Metadata
- Authors
- Karter, A. J., Ahmed, A. T., Liu, J., Moffet, H. H., & Parker, M. M.
- Venue
- Diabetic Medicine
- Publisher
- Wiley
- Published
- 2005-07-13
- Volume
- 22
- Issue
- 8
- Pages
- 986-993
- ISSN
- 0742-3071 (ISSN-L)
- 1464-5491
- OpenAlex
- W2154572400
- Cited by
- 90
- References
- 9
- FWCI
- 7.48
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pioglitazone initiation and subsequent hospitalization for congestive heart failure. https://app.cochat.ai/papers/10.1111/j.1464-5491.2005.01704.x
- The paper
- Karter, A. J., Ahmed, A. T., Liu, J., Moffet, H. H., & Parker, M. M. (2005). Pioglitazone initiation and subsequent hospitalization for congestive heart failure. Diabetic Medicine. https://doi.org/10.1111/j.1464-5491.2005.01704.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.